BioVie IncChange company Symbol lookupSelect an option...BIVI BioVie IncBOF BranchOut Food IncVINO Gaucho Group Holdings IncONVO Organovo Holdings IncZBRA Zebra Technologies CorpBROG Brooge Energy LtdNTZ Natuzzi SpAGE General Electric CoOST Ostin Technology Group Co LtdCHEA Chenghe Acquisition CoGo
BioVie Inc. is a clinical-stage company engaged in developing drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company’s drug candidate NE3107 inhibits inflammatory activation of extracellular single-regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions. In liver disease, its orphan drug candidate BIV201 (continuous infusion terlipressin) is for the treatment of refractory ascites due to liver cirrhosis. BIV201 is administered as a liquid formulation. The Company is also engaged in developing NE3107, an extracellular single-regulated kinase (ERK) inhibitor that selectively reduces neuroinflammation and insulin resistance. NE3107 is an orally administered small molecule to inhibit inflammation-driven insulin resistance and pathological inflammatory cascades.
|
|
|
|
| |
Company Profile
BioVie Inc. is a clinical-stage company engaged in developing drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company’s drug candidate NE3107 inhibits inflammatory activation of extracellular single-regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions. In liver disease, its orphan drug candidate BIV201 (continuous infusion terlipressin) is for the treatment of refractory ascites due to liver cirrhosis. BIV201 is administered as a liquid formulation. The Company is also engaged in developing NE3107, an extracellular single-regulated kinase (ERK) inhibitor that selectively reduces neuroinflammation and insulin resistance. NE3107 is an orally administered small molecule to inhibit inflammation-driven insulin resistance and pathological inflammatory cascades.
Valuation Ratios
- Price/Earnings (TTM)
- --
- Price/Sales (TTM)
- --
- Price/Book (MRQ)
- 7.53x
- Price/Cash Flow (TTM)
- --
MRQ = Most Recent Quarter
Price Performance
Financial Statements
Balance sheet
Values displayed are in thousands.
Income statement
Values displayed are in thousands.
Cash flow
Values displayed are in thousands.
Company Officers
- James Lang
- Cuong Viet DoPres.
- Joanne Wendy KimCFO
- Clarence N. AhlemExec.VP
- Penelope MarkhamExec.VP
Address
- 680 W Nye Lane, Suite 201
- Carson City, NV 89703
- Phone: (775) 888-3162
- https://www.bioviepharma.com/
Insider Trading
During the most recent quarter, 41K shares were sold in insider trading.
Insider trading information report provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.